bm 13505 has been researched along with thromboxane a2, carbocyclic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishii, A; Kishibayashi, N; Miki, I; Nonaka, H; Obase, H; Ohshima, E; Takami, H | 1 |
1 other study(ies) available for bm 13505 and thromboxane a2, carbocyclic
| Article | Year |
|---|---|
Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Benzimidazoles; Benzoxepins; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Guinea Pigs; Humans; Hydrazines; In Vitro Techniques; Kinetics; Prostaglandin Endoperoxides, Synthetic; Radioligand Assay; Rats; Receptors, Thromboxane; Species Specificity; Thromboxane A2; Tritium; Vasoconstrictor Agents | 1992 |